高カルシウム血症治療の世界市場ー産業および機会分析ー2016-2026:ビスフォスフォネート、カルシトニン、グルココルチコイド、デノスマブ、カルシウム受容体刺激薬

【英語タイトル】Hypercalcemia Treatment Market: Global Industry Analysis & Opportunity Assessment, 2016-2026

Future Market Insightsが出版した調査資料(FMI612028)・商品コード:FMI612028
・発行会社(調査会社):Future Market Insights
・発行日:2016年9月27日
・ページ数:135
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Individual (single user)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
EnterpriseUSD10,000 ⇒換算¥1,130,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Hypercalcemia is a condition caused by above normal levels of calcium in the body, with serum calcium level greater than 2.6 mmol/L. It is a life threatening metabolic disorder associated with neoplastic diseases and occurs in 10% to 20% of all adults suffering from cancer; particularly lung and breast cancer, and myeloma.
Early diagnosis of hypercalcemia by hydration and treatment with agents – to decrease serum calcium concentrations – also known as hypocalcemic drugs can produce symptomatic improvements within three to five days. The scope of hypercalcemia treatment market study is for Bisphosphonates (Clodronate, Etidronate, Ibandronate, Pamidronate and Zoledronic acid), Calcitonin, Glucocorticoids, Denosumab and Calcimimetics for treatment of malignancy-related hypercalcemia.

Market Dynamics

Primary factors fuelling demand for hypercalcemia treatment include increasing prevalence of hyperparathyroidism-related hypercalcemia, growing number of patients with cancers, higher incidence of multiple myeloma, availability of appropriate drug therapy alternatives over surgery, favourable reimbursement scenario and drug therapies to avoid kidney failure.

Market Segmentation by Product Type

Based on product type, the market has been segmented into Bisphosphonates (Clodronate, Etidronate, Ibandronate, Pamidronate and Zoledronic acid), Calcitonin, Glucocorticoids, Denosumab and Calcimimetics.

Market Segmentation by Distribution Channel

Revenue from the independent pharmacy and drug stores segment is expected to grow at a very fast pace, and contribute significantly towards distribution of hypercalcemia drugs during the forecast period. Hospitals distribution channel segment is projected to generate comparatively high revenue owing to novel and easy availability of hypercalcemia treatment drugs worldwide.

Market Value and Forecast

Global hypercalcemia treatment market revenue is projected to expand at a CAGR of 11.2% during forecast period 2016–2026, and a reach a value of US$ 25,230.2 Mn by the end of 2026.

Key Regions

The global hypercalcemia treatment market has been segmented into seven major regions: North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan (APEJ), Japan and Middle East & Africa (MEA). In terms of value, North America is estimated to be the dominant market in 2016 end, with revenue contribution expected to expand at a CAGR of 11.4% over the forecast period. Also, North America is estimated to witness comparatively faster growth in terms of revenue over the forecast period. Western Europe hypercalcemia treatment market is expected to register a CAGR of 11.3% in revenue terms over the forecast period. Bisphosphonates segment revenue in the North America hypercalcemia treatment market is expected to register a CAGR of 11.3% over the forecast period, with growth driven by increasing prevalence of cancer and myeloma among the populace in the region.

global hypercalcemia treatment market

Key Players

Some key players in the global hypercalcemia treatment market that have been identified in this report include Bayer Pharma AG, Sun Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., Amgen Inc., Novartis AG, Dr. Reddy’s Laboratories Ltd. and Cipla Inc. The report also identifies company-specific strategies related to market consolidation initiatives and analysis of their specific strengths, weaknesses, opportunities and threats.

【レポートの目次】

Table Of Content
1. Executive Summary

2. Market Introduction

2.1. Market Definition

2.2. Market Taxonomy

3. Global Hypercalcemia Treatment Market Analysis Scenario

3.1. Market Size (US$ Mn) and Forecast

3.1.1. Market Size and Y-o-Y Growth

3.1.2. Absolute $ Opportunity

4. Market Dynamics

4.1. Macro-economic Factors

4.2. Drivers

4.2.1. Supply Side

4.2.2. Demand Side

4.3. Restraints

4.4. Opportunity

5. Global Hypercalcemia Treatment Market Analysis and Forecasts, By Product Type

5.1. Introduction

5.2. Basis Point Share (BPS) Analysis By Product Type

5.3. Y-o-Y Growth Projections By Product Type

5.4. Market Value Forecast By Product Type , 2014–2026

5.4.1. Bisphosphonates

5.4.1.1. Clodronate

5.4.1.2. Etidronate

5.4.1.3. Ibandronate

5.4.1.4. Pamidronate

5.4.1.5. Zoledronic acid

5.4.2. Calcitonin

5.4.3. Glucocorticoids

5.4.4. Denosumab

5.4.5. Calcimimetics

5.5. Prominent Trends

5.6. Market Attractiveness By Product Type

6. Global Hypercalcemia Treatment Market Analysis and Forecasts, By Distribution Channel

6.1. Introduction

6.2. Basis Point Share (BPS) Analysis By Distribution Channel

6.3. Y-o-Y Growth Projections By Distribution Channel

6.4. Market Value Forecast By Distribution Channel , 2014–2026

6.4.1. Hospitals

6.4.2. Clinics

6.4.3. Independent Pharmacy and Drug Stores

6.5. Prominent Trends

6.6. Market Attractiveness By Distribution Channel

7. Global Hypercalcemia Treatment Market Analysis and Forecasts, By Region

7.1. Basis Point Share (BPS) Analysis By Region

7.2. Y-o-Y Growth Projections By Region

7.3. Market Value Forecast By Region

7.3.1. North America

7.3.2. Latin America

7.3.3. Western Europe

7.3.4. Eastern Europe

7.3.5. APEJ

7.3.6. Japan

7.3.7. MEA

7.4. Market Attractiveness By Country/Region

8. North America Hypercalcemia Treatment Market Analysis and Forecast

8.1. Introduction

8.1.1. Basis Point Share (BPS) Analysis By Country

8.1.2. Y-o-Y Growth Projections By Country

8.2. Market Value Forecast By Product Type , 2014–2026

8.2.1. Bisphosphonates

8.2.1.1. Clodronate

8.2.1.2. Etidronate

8.2.1.3. Ibandronate

8.2.1.4. Pamidronate

8.2.1.5. Zoledronic acid

8.2.2. Calcitonin

8.2.3. Glucocorticoids

8.2.4. Denosumab

8.2.5. Calcimimetics

8.3. Market Value Forecast By Distribution Channel , 2014–2026

8.3.1. Hospitals

8.3.2. Clinics

8.3.3. Independent Pharmacy and Drug Stores

8.4. Market Value Forecast By Country , 2014–2026

8.4.1. U.S.

8.4.2. Canada

8.5. Market Attractiveness Analysis

8.5.1. By Product Type

8.5.2. By Distribution Channel

8.5.3. By Country

8.6. Prominent Trends

8.7. Drivers and Restraints: Impact Analysis

9. Latin America Hypercalcemia Treatment Market Analysis and Forecast

9.1. Introduction

9.1.1. Basis Point Share (BPS) Analysis By Country

9.1.2. Y-o-Y Growth Projections By Country

9.2. Market Value Forecast By Product Type , 2014–2026

9.2.1. Bisphosphonates

9.2.1.1. Clodronate

9.2.1.2. Etidronate

9.2.1.3. Ibandronate

9.2.1.4. Pamidronate

9.2.1.5. Zoledronic acid

9.2.2. Calcitonin

9.2.3. Glucocorticoids

9.2.4. Denosumab

9.2.5. Calcimimetics

9.3. Market Value Forecast By Distribution Channel , 2014–2026

9.3.1. Hospitals

9.3.2. Clinics

9.3.3. Independent Pharmacy and Drug Stores

9.4. Market Value Forecast By Country , 2014–2026

9.4.1. Brazil

9.4.2. Mexico

9.4.3. Argentina

9.4.4. Rest Of Latin America

9.5. Market Attractiveness Analysis

9.5.1. By Product Type

9.5.2. By Distribution Channel

9.5.3. By Country

9.6. Prominent Trends

9.7. Drivers and Restraints: Impact Analysis

10. Western Europe Hypercalcemia Treatment Market Analysis and Forecast

10.1.Introduction

10.1.1. Basis Point Share (BPS) Analysis By Country

10.1.2. Y-o-Y Growth Projections By Country

10.2.Market Value Forecast By Product Type , 2014–2026

10.2.1. Bisphosphonates

10.2.1.1. Clodronate

10.2.1.2. Etidronate

10.2.1.3. Ibandronate

10.2.1.4. Pamidronate

10.2.1.5. Zoledronic acid

10.2.2. Calcitonin

10.2.3. Glucocorticoids

10.2.4. Denosumab

10.2.5. Calcimimetics

10.3.Market Value Forecast By Distribution Channel , 2014–2026

10.3.1. Hospitals

10.3.2. Clinics

10.3.3. Independent Pharmacy and Drug Stores

10.4.Market Value Forecast By Country , 2014–2026

10.4.1. Germany

10.4.2. UK

10.4.3. France

10.4.4. Italy

10.4.5. Spain

10.4.6. Nordic countries

10.4.7. Rest Of Western Europe

10.5.Market Attractiveness Analysis

10.5.1. By Product Type

10.5.2. By Distribution Channel

10.5.3. By Country

10.6. Prominent Trends

10.7. Drivers and Restraints: Impact Analysis

11. Eastern Europe Hypercalcemia Treatment Market Analysis and Forecast

11.1.Introduction

11.1.1. Basis Point Share (BPS) Analysis By Country

11.1.2. Y-o-Y Growth Projections By Country

11.2.Market Value Forecast By Product Type , 2014–2026

11.2.1. Bisphosphonates

11.2.1.1. Clodronate

11.2.1.2. Etidronate

11.2.1.3. Ibandronate

11.2.1.4. Pamidronate

11.2.1.5. Zoledronic acid

11.2.2. Calcitonin

11.2.3. Glucocorticoids

11.2.4. Denosumab

11.2.5. Calcimimetics

11.3.Market Value Forecast By Distribution Channel , 2014–2026

11.3.1. Hospitals

11.3.2. Clinics

11.3.3. Independent Pharmacy and Drug Stores

11.4.Market Value Forecast By Country , 2014–2026

11.4.1. Russia

11.4.2. Poland

11.4.3. Rest Of Eastern Europe

11.5.Market Attractiveness Analysis

11.5.1. By Product Type

11.5.2. By Distribution Channel

11.5.3. By Country

11.6. Prominent Trends

11.7. Drivers and Restraints: Impact Analysis

12. APEJ Hypercalcemia Treatment Market Analysis and Forecast

12.1.Introduction

12.1.1. Basis Point Share (BPS) Analysis By Country

12.1.2. Y-o-Y Growth Projections By Country

12.2.Market Value Forecast By Product Type , 2014–2026

12.2.1. Bisphosphonates

12.2.1.1. Clodronate

12.2.1.2. Etidronate

12.2.1.3. Ibandronate

12.2.1.4. Pamidronate

12.2.1.5. Zoledronic acid

12.2.2. Calcitonin

12.2.3. Glucocorticoids

12.2.4. Denosumab

12.2.5. Calcimimetics

12.3.Market Value Forecast By Distribution Channel , 2014–2026

12.3.1. Hospitals

12.3.2. Clinics

12.3.3. Independent Pharmacy and Drug Stores

12.4.Market Value Forecast By Country , 2014–2026

12.4.1. China

12.4.2. India

12.4.3. ASEAN

12.4.4. Australia & New Zealand

12.4.5. Rest Of APEJ

12.5.Market Attractiveness Analysis

12.5.1. By Product Type

12.5.2. By Distribution Channel

12.5.3. By Country

12.6. Prominent Trends

12.7. Drivers and Restraints: Impact Analysis

13. Japan Hypercalcemia Treatment Market Analysis and Forecast

13.1.Introduction

13.1.1. Basis Point Share (BPS) Analysis By Country

13.1.2. Y-o-Y Growth Projections By Country

13.2.Market Value Forecast By Product Type , 2014–2026

13.2.1. Bisphosphonates

13.2.1.1. Clodronate

13.2.1.2. Etidronate

13.2.1.3. Ibandronate

13.2.1.4. Pamidronate

13.2.1.5. Zoledronic acid

13.2.2. Calcitonin

13.2.3. Glucocorticoids

13.2.4. Denosumab

13.2.5. Calcimimetics

13.3.Market Value Forecast By Distribution Channel , 2014–2026

13.3.1. Hospitals

13.3.2. Clinics

13.3.3. Independent Pharmacy and Drug Stores

13.4.Market Attractiveness Analysis

13.4.1. By Product Type

13.4.2. By Distribution Channel

13.5. Prominent Trends

13.6. Drivers and Restraints: Impact Analysis

14. MEA Hypercalcemia Treatment Market Analysis and Forecast

14.1.Introduction

14.1.1. Basis Point Share (BPS) Analysis By Country

14.1.2. Y-o-Y Growth Projections By Country

14.2.Market Value Forecast By Product Type , 2014–2026

14.2.1. Bisphosphonates

14.2.1.1. Clodronate

14.2.1.2. Etidronate

14.2.1.3. Ibandronate

14.2.1.4. Pamidronate

14.2.1.5. Zoledronic acid

14.2.2. Calcitonin

14.2.3. Glucocorticoids

14.2.4. Denosumab

14.2.5. Calcimimetics

14.3.Market Value Forecast By Distribution Channel , 2014–2026

14.3.1. Hospitals

14.3.2. Clinics

14.3.3. Independent Pharmacy and Drug Stores

14.4.Market Value Forecast By Country , 2014–2026

14.4.1. GCC Countries

14.4.2. South Africa

14.4.3. North Africa

14.4.4. Rest Of MEA

14.5.Market Attractiveness Analysis

14.5.1. By Product Type

14.5.2. By Distribution Channel

14.5.3. By Country

14.6. Prominent Trends

14.7. Drivers and Restraints: Impact Analysis

15. Competition Landscape

15.1.Competition Dashboard

15.2.Market Share Analysis By Company (2015)

15.3.Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)

15.3.1. Bayer Pharma AG

15.3.2. Sun Pharmaceutical Industries Ltd.

15.3.3. Mylan N.V.

15.3.4. Pfizer Inc.

15.3.5. Amgen Inc.

15.3.6. Novartis AG

15.3.7. Dr. Reddy’s Laboratories Ltd.

15.3.8. Cipla Inc.

16. Assumptions and Acronyms Used

17. Research Methodology



【レポートのキーワード】

高カルシウム血症治療、ビスフォスフォネート、カルシトニン、グルココルチコイド、デノスマブ、カルシウム受容体刺激薬

★調査レポート[高カルシウム血症治療の世界市場ー産業および機会分析ー2016-2026:ビスフォスフォネート、カルシトニン、グルココルチコイド、デノスマブ、カルシウム受容体刺激薬] (コード:FMI612028)販売に関する免責事項を必ずご確認ください。
★調査レポート[高カルシウム血症治療の世界市場ー産業および機会分析ー2016-2026:ビスフォスフォネート、カルシトニン、グルココルチコイド、デノスマブ、カルシウム受容体刺激薬]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆